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Introduction  
Type 1 diabetes mellitus (T1D) is one of the most 
common autoimmune diseases with several million 
people already affected around the globe. It can 
occur at any age, but is most commonly diagnosed 
from infancy to the late thirties. It is characterized 
by an absolute loss of insulin secretion, and results 
from an autoimmune process that destroys insulin-
producing ß cells within the pancreatic islet. Similar 
to other autoimmune diseases, the etiology of T1D 
remains obscure but develops on a genetically 
susceptible background and also involves a variety 
of factors, ranging from immune dysregulation to 
environmental triggers. The outcome is the 
production of auto-antibodies as well as an 
expansion of auto-aggressive T cells.1  
The incidence of T1D worldwide varies 
between as high as 30-40 per    100 000  children in 
Finland and Sardinia to values as low as 30-40 per 
100 000  children in Japan and China 2 .In Egypt , 
the prevalence of T1D in school aged children 
varies between 1.12- 1.9 per 1000  in various 
studies 3-4. Worldwide, the incidence of T1D is 
increasing, particularly in the under-5-years age 
group.1 The standardized mortality ratio for T1D has 
been estimated as 4-fold for females and 2.7-fold 
for males in the Western countries. Even with tight 
glucose control, there is a significant risk of 
neuropathy, retinopathy and nephropathy, as well as 
a 3-fold increase in the risk of severe 
hypoglycaemia.5 
Understanding the pathology of T1D may help 
improve prevention and management. This review 
will focus on the immunology of T1D, and how this 
understanding may influence the clinical 
management, and development of new treatments 
for this disease.  
 
The immune nature of type 1 diabetes 
There are over one million islets in a healthy adult 
pancreas. They make up 1% of the total pancreatic 
volume, weigh about 1 g, and contain about 1 mg of 
insulin. Histological analysis of the pancreas from 
patients with T1D shows immunological activity 
limited to insulin-containing islets, including 
infiltration by activated lymphocytes, antibodies 
and components of the complement system. These 
histological findings are consistent with TD1 being 
an immune-mediated disease. 6 
Further evidence comes from studies showing 
that T1D is characterized by the presence of 
antibody (humoral) and T-cell (cellular) responses 
to islet proteins (antigens) (Table 1). Immune 
responses to these antigens predate the clinical onset 
of diabetes, giving further support for an immune 
etiology to T1D (Table 2).  
 
 
Table 1. The major ß cell autoantigens in type 1 
diabetes 1,6 
 
Islet cell antigen 
(ICA) 
The first islet ‘autoantigen’ to be 
described. Now known to be a 
complex of autoantigens. 
Antibodies to ICA are present in 
90% of type 1 diabetes patients at 
the time of diagnosis. 
Insulin and pro-
insulin 
Antibodies to insulin and pro-
insulin, the biochemical precursor 
to insulin, are present at diagnosis 





A constituent of the ICA antigen 
complex. Present in the 65 kDa 
form in the human islet. Also 
present in the central nervous 
system. GAD antibodies are 
present in 73% of type 1 diabetes 




A transmembrane protein from the 
insulin secretory granule. Also 
present in central nervous tissue. 
IA-2 antibodies are present in 75% 





Table 2. Evidence for an immune etiology to type 1 
diabetes1 
 
1. Pancreatic ß cells contain immune cell infiltrates. 
2. Immunosuppressive drugs reduce disease incidence. 
3. ß cell immunity predates disease onset. 
4. HLA genes associate with disease risk or protection. 







The natural history of type 1 diabetes  
This is best demonstrated by looking at the 
prospective studies investigating the natural history 
of T1D.7 The German BABYDIAB study 
commenced in 1989 to prospectively investigate 
islet autoantibody and diabetes development in 
newborn offspring of parents with T1D.8 Currently, 
it represents the longest-running prospective study 
from birth examining the risks for islet 
autoimmunity and T1D. A total of 1,642 offspring 
have been recruited at birth and participated in the 
investigation. The Finnish type 1 Diabetes 
Prediction and Prevention (DIPP) project 9 started in 
1994 and followed up newborn infants with 
increased genetic risk at close intervals for up to 10 
years as well as relatives of patients with T1D. 
Similar prospective studies include the American 
(DAISY) study10, the Australian BABYDIAB study 
11, and the MIDIA study on Norwegian children.12   
 
Early characteristics of islet autoimmunity   
Children developing T1D in early childhood (<10 
years of age) have the first signs of islet 
autoimmunity very early in life, with the majority 
by 2 years of age.13 Around 4% of offspring of 
parents with T1D in the BABYDIAB study and 
around 6% of genetically at-risk infants from the 
general population in the Finnish DIPP study have 
developed islet autoantibodies by age 2 years.13 
Children who develop autoantibodies within the 
first 2 years of life are those who most often 
develop multiple islet autoantibodies and progress 
to T1D in childhood.14 Autoantibodies do not 
exclusively develop before age 2 years, but children 
who develop autoantibodies later have a slower 
progression to multiple antibodies and T1D.7 
Islet cell autoantibodies (IAAs) are usually the 
first autoantibodies detected.15 Children who 
progress to T1D have IAAs of high affinity15 and 
also develop GADAs concomitantly or soon after 
the first IAA response. Spreading of the response to 
IA-2 and IA-2ß often follows.13,14 Overall, 
autoantibodies of the IgG1 subclass are the 
dominant component of the early humoral immune 
response against each islet antigen, and other 
subclasses are usually only detected during high-
titer peak IgG1 responses.6,15 
Once islet autoantibodies appear, they usually 
persist, although significant fluctuations in antibody 
titer can be observed during the pre-diabetic phase.6 
Of the three islet autoantibodies discussed, IAAs are 
reported to be the least persistent. One reason why 
IAAs, and indeed GADAs or IA-2As, may not 
persist is because they may be transferred from the 
mother with T1D during pregnancy.7,12 Depending 
on the titer of antibodies in the mother, maternal 
insulin antibodies can persist in the circulation of 
the child for up to 1 year and maternal GADAs for 
up to 18 months.7,12 
 
Autoantibody effects on antigen presentation 
One potential important role played by 
autoantibodies in the T1D disease process is their 
effect on autoantigen processing and presentation 
by class II major histocompatibility complexes. 
Antigen-presenting cells can capture antigen for 
presentation to the immune system via both specific 
and nonspecific mechanisms1. Antigen-specific B-
cell receptors and Fc receptors on monocytes, 
macrophages, and dendritic cells increase the 
efficiency of antigen capture by the antigen-
presenting cells and thus lower the threshold for a 
T-cell response. Several sets of experiments have 
demonstrated that, in the presence of 
autoantibodies, the T-cell response to autoantigen is 
either enhanced or shifted in its focus.6 This has led 
to the hypothesis that the process of antibody-
mediated antigen internalization alters 
postendocytic transport and processing events, 
resulting in the presentation of different T-cell 
epitopes and potentially unmasking "cryptic" self-
determinants, thus manipulating the T-cell 
response.6,16,17 
 
Genetic factors influencing the development of 
islet autoimmunity 
Islet autoimmunity and T1D develop in genetically 
susceptible individuals, and a major risk factor is a 
first-degree T1D family history.18 Familial 
aggregation of T1D has been recognized for many 
years, and ~10–13% of newly diagnosed children 
have a first-degree relative affected with T1D.19 
With respect to family history, risk of developing 
islet autoimmunity varies depending on which 
relative(s) have T1D. In the Diabetes Prevention 
Trial 1 (DPT-1), siblings of type 1 diabetic patients 
developed islet autoantibodies more frequently than 
offspring or parents of type 1 diabetic patients.20  
The MHC region on human chromosome 6p21 
has been identified as a critical susceptibility locus 
for many human autoimmune diseases, including 
T1D. The major T1D susceptibility genes are found 
within the HLA class II region on chromosome 
6p21 (IDDM1).18 HLA genes are thought to 
contribute as much as 50% of the genetic risk for 
T1D. Remarkable with respect to HLA genotypes is 
that, whereas several genotypes confer increased 
risk, other genotypes confer protection (e.g., 
genotypes containing the HLA DQ6 haplotype).21 In 
Caucasians, islet autoimmunity and T1D are 
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strongly associated with HLA DR3-DQ2 and DR4-
DQ8 haplotypes), and recent studies from different 
European countries have confirmed that the HLA 
DR3-DQ2/DR4-DQ8 genotype is associated with 
the highest diabetes risk21. This genotype is found in 
20–30% of type 1 diabetic patients and in almost 
50% of patients diagnosed in early childhood.22  
Islet autoantibodies differ in their association 
with HLA haplotypes. GADAs are more frequent in 
patients with HLA DR3-DQ2, whereas IAAs and 
IA-2As are more frequent in patients with HLA 
DR4-DQ8. Patients without these haplotypes are 
more frequently islet autoantibody negative.6,7  
HLA haplotypes can also be used to identify 
children who are more likely to develop islet 
autoantibodies. Results from longitudinal studies of 
children carrying high-risk HLA genotypes 
revealed that they have a higher risk for early and 
more frequent development of islet autoantibodies 
in infancy.14 Among BABYDIAB offspring, the 
risk of developing islet autoantibodies by age 2 
years is 20% in individuals who have the high-risk 
DR3-DQ2/DR4-DQ8 or DR4-DQ8/DR4-DQ8 
genotypes compared with 2.7% in offspring without 
these genotypes, and, overall, 50% of islet 
autoantibody–positive offspring have at least one of 
these genotypes.20  
A second genetic susceptibility locus has been 
mapped by a variable number of tandem repeat 
(VNTR) in the insulin gene (INS) promoter region 
on chromosome 11p15 (IDDM2). Risk has been 
suggested to be conferred by different expression of 
the insulin protein in the thymus, leading to 
defective central tolerance to the insulin molecule.23 
In accordance with this, IAAs are less frequent in 
patients or relatives who have the T1D protective 
INS VNTR class I/III or III/III genotypes. 
Combining HLA and INS genotyping, therefore, 
will improve T1D risk stratification.7   
Over the last decade, whole genome screens 
have indicated that there are at least 15 other loci 
associated with T1D,14,18 and of those, another 2 
genes intimately associated with T-cell activation 
have been identified recently. An allele of the gene 
for a negative regulator of T-cell activation, 
cytotoxic T lymphocyte antigen 4 (CTLA-4), found 
on chromosome 2q33, is considered to be the third 
susceptibility locus for T1D and has been associated 
with increased levels of soluble CTLA-4 and the 
frequency of regulatory T cells.23,19 A variant of 
PTPN22, the gene encoding LYP, also a suppressor 
of T-cell activation, has been deemed the fourth 
susceptibility factor.22,24 The observation that the 4 
most important susceptibility genes for T1D can all 
be represented on a single diagram of antigen 
presentation to T cells (Figure 1) emphasizes the 
potential importance of current therapeutic 
strategies targeting this interaction. It is also worth 
noting that the HLA, CTLA-4 and PTPN22 have all 
been implicated in autoimmune thyroid disease and 
other autoimmune diseases, which supports the 
premise that similar or overlapping biological 
pathways contribute to different autoimmune 
diseases.25 Modification of risk for islet 
autoimmunity and T1D by the environment is also 
likely to be genotype specific, as shown for early 
exposure to cereals.7,26 
 
Environmental factors influencing the 
development of islet autoimmunity 
Studies in monozygotic twins have demonstrated a 
concordance rate of ~50%, suggesting that 
environmental factors play a role in the 
development of diabetes. Epidemiologic studies 
suggest that viruses, nutrition, toxic agents, or 
psychosocial factors may contribute to the etiology 
alone or in combination. As indicated in Fig.2, the 
long interval between exposure and clinical 
diagnosis, as well as the interaction of multiple 
genes, insults, or both, complicate the identification 
of triggers.6,25 
 
Dietary factors and islet autoimmunity  
Early feeding may influence the risk of type 1 
(T1D) later in life. The information generated so far 
is, however, controversial. Long breastfeeding, 
exclusive breastfeeding in particular, and 
supplementation with vitamin D in infancy have 
been reported to confer partial protection against 
beta-cell autoimmunity and TID. In contrast, early 
exposure to cow's milk proteins and cereals and 
heavy weight in infancy have been implicated as 
risk factors for T1D.27-29 
A recent study 30 investigated the relation 
between duration of breast-feeding and beta-cell 
autoantibodies in 5-year-old non-diabetic children 
in a prospective population-based follow-up; the 
results revealed positive association between a short 
duration of both total and exclusive breast-feeding, 
as well as an early introduction of formula, and 
positivity for beta-cell autoantibodies in children 
from the general population suggesting that breast-
feeding modifies the risk of beta-cell autoimmunity, 






Figure 1. Representation of the process whereby antigen (in this case peptides of proinsulin) is presented to 
CD4 T cells by human leukocyte antigen (HLA) class II molecules on the antigen presenting cell. This 
results in T-cell activation. In this diagram the 4 major genes associated with type 1 diabetes are present. 
CTLA-4 is an inhibitor of T-cell activation, as is lymphoid tyrosine phosphatase (LYP), which is encoded by 
the gene PTPN22. The complex of LYP–C-terminal Src kinase (CSK) inhibits Lck signaling after 








Figure 2. Two-stage development of type 1 diabetes. Step one is the development of persistent islet 
autoimmunity measured by the presence of GAD65, IA-2, or insulin autoantibodies, alone or in combination. 




Viral infections and islet autoimmunity 
Viruses may induce islet autoimmunity by 
molecular mimicry between amino acid sequences 
of viral peptides and islet antigens that can activate 
autoreactive T-cells, by bystander activation and 
expansion of previously activated autoreactive T-
cells at a local inflammatory site (including the 
spreading of T-cell responses to other epitopes on 
islet antigens), and by nonspecific activation of 
autoreactive T-cells through viral 
superantigens.7,25,31 It is possible that many common 
RNA viral infections may induce islet 
autoimmunity in genetically susceptible patients. 
Prenatal rubella infection in the first trimester is the 
best-established example of viral initiation of T1D. 
Twenty percent of patients with congenital rubella 
develop the disease.37 Acute enterovirus infections, 
Coxsackie virus B4 infection and recently rotavirus 
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have also been associated with the appearance of 
serum autoantibodies to islet antigens by some 
investigators10,31,32 but others could not confirm 
such observations.33,34 Infection with other viruses, 
such as mumps and human cytomegalovirus (CMV) 
and rotaviruses have also been suggested to be 
diabetogenic in susceptible individuals.37 
 
Progression from islet autoantibody positivity to 
type 1 diabetes 
Once islet autoantibodies (one or several) have 
developed, the next question is what factors 
determine ß-cell killing to the extent that diabetes 
develops. 
 
Factors affecting progression to disease 
Genes 
Genes clearly determine the likelihood of 
developing islet autoantibodies and progression to 
multiple islet autoantibodies. It remains 
controversial. However, if progression from 
multiple islet autoantibodies to T1D is influenced 
by genetic factors.7 Most studies have stratified 
progression to T1D using the HLA genotype in 
autoantibody-positive relatives without 
distinguishing multiple- from single-antibody 
positivity. In these studies, the presence of the 
protective HLA alleles DQB1*0602 allele , or 
DPB1*0402  or, HLA DR2 were associated with 
decreased progression to T1D,35-37 and the high-risk 
HLA DR3/4 genotype was associated with 
increased progression to T1D.20,23,38  
Environment 
Like genes, the same environmental factors 
discussed as triggers of islet autoimmunity are also 
claimed as possible accelerators or protectors of 
progression to T1D. Few hard data are available, 
however.6,37 
Age 
Age affects the risk of progression to T1D.39 
According to the BABYDIAB study, the risk for 
developing T1D can also be stratified on the basis 
of how early islet autoantibodies develop. 
Progression to diabetes is significantly faster in 
individuals who have multiple islet autoantibodies 
already within the first year of life than in 
individuals who develop multiple islet 
autoantibodies at age 2 or 5 years.7,39 Thus, delaying 
progression to multiple antibodies may be effective 
in markedly delaying diabetes onset.  
 
Characteristics of autoantibodies in progressors 
versus nonprogressors 
It is conceivable that the development of diabetes is 
accompanied by a maturation of the autoimmune 
response. It is now well established that subjects 
with multiple islet autoantibodies have considerably 
increased rates of progression to T1D than subjects 
with only one islet autoantibody.12,40 Substantial 
effort has been made to identify other disease-
specific characteristics of autoantibodies that will 
help distinguish who will and who won’t develop 
T1D and who will develop T1D early and late.15,41  
 
Autoantibody affinity determines progression  
The affinity of IAAs and GAD antibodies (GADA) 
has been found to vary considerably among IAA-
positive children.42,43 IAAs range from high-affinity 
IgG in most individuals through to low-affinity 
cold-reactive IgM antibodies in others 15. Children 
who developed high-affinity IAAs (Kd >109 l/mol) 
have persistent IAAs, develop multiple islet 
autoantibodies, and have a 50% risk for developing 
T1D within 6 years. In contrast, children who have 
IAAs of lower affinity infrequently progress to 
multiple islet autoantibodies or T1D. High-affinity 
IAAs differ from lower-affinity IAAs in their 
insulin-binding characteristics in a manner 
consistent with distinct epitope recognition and in 
contrast to the lower-affinity IAAs (which often do 
not bind proinsulin). In a recent study42 it was found 
that children develop discrete, heterogeneous 
antibody responses to GAD, only some of which 
are diabetes relevant. Subtyping the GADA 
responses using affinity measurement improves 
T1D risk assessment. 
 
Progressors have broader autoantibody 
responses 
The breadth of the autoantibody response can be 
measured by the number of autoantibody epitopes it 
is directed against, and probably by the subclass 
usage.6,41 
It is hypothesized that the initial autoantibody 
response in pre-diabetic subjects, as well as healthy 
subjects not at risk for T1D, is IgM specific. In 
progressors, the autoantibody response in pre–type 
1 diabetic individuals switches to an IgG-dominated 
response. Isotype switching reflective of Th1 
activity is observed in individuals who progress to 
T1D more often than nonprogressors or individuals 
with slow progression.6 
In a recent analysis of autoantibody-positive 
relatives followed longitudinally, the highest risks 
for T1D were associated with high titer IAA and 
IA-2A responses, with the appearance of antibody 
subclasses IgG2, IgG3, and/or IgG4 of IAA and IA-





Association of type 1 diabetes with other 
autoimmune diseases 
Patients and relatives with T1D are at increased risk 
of other immune mediated diseases. These most 
commonly include thyroid disease, celiac disease, 
autoimmune gastritis and Addison's disease.1 
Thyroid disease 
Prevalence of thyroiditis in the diabetic population 
is considerably higher than in the general 
population. Up to 25% of patients with T1D will 
have evidence of thyroid disease (the commonest 
autoimmune disease associated with T1D).44 Most 
of these T1D patients will have subclinical disease, 
although about 5% will be clinically hypothyroid. 
Undiagnosed hypothyroidism can affect glycemic 
and lipid control in patients with T1D, making a 
good case for regular routine screening for this 
condition.45  
Annual laboratory determinations of anti-
thyroid peroxidase (TPO) antibodies and TSH 
should be part of routine tests in the diabetic 
population, especially in girls, children with T1D 
for > 9 years, patients above 12 years of age, and 
those in whom T1D is associated with another 
autoimmune disease. Anti-thyroid antibody 
positivity may indicate the necessity for thyroid 
function testing at shorter intervals.46 
Celiac disease 
Celiac disease is a gluten-sensitive enteropathy, 
prevalent at up to 1% of the Caucasian population, 
and treated by strict avoidance of gluten-containing 
products. The prevalence of celiac disease is 
increased at 7% in subjects with T1D.47 Many 
patients with celiac disease do not describe the 
symptoms of tiredness, diarrhea, steatorrhea or 
weight loss traditionally associated with this 
disease, and up to 40% can be asymptomatic.1 The 
risks of T1D and celiac disease being present 
together are higher at a younger age of onset and in 
the female sex. Screening is through measurement 
of serum anti-endomysial and anti-transglutaminase 
antibodies, with confirmatory biopsy of the 
duodenum through upper gastro-intestinal 
endoscopy. Antibody levels can fluctuate and 
screening should be conducted at regular intervals, 
particularly where clinical suspicion exists.48 
Autoimmune gastritis 
The gastric sodium-potassium ATPase appears to 
be the major autoantigen in autoimmune gastritis, 
manifesting achlorhydria and iron deficiency 
anemia. Parietal cell antibodies are a marker of 
pernicious anemia, and are present in up to 20% of 
patients with T1D. This necessitates regular 
screening for these conditions, at least with a full 
blood count.44  
Addison's disease 
The earliest descriptions of islet cell antibody were 
in patients with Addison's disease, and the 
prevalence of islet cell antibody has been reported 
to be as high as 6% in patients with Addison's 
disease.47 Conversely, the prevalence of antibodies 
to 21 hydroxylase, a marker of autoimmune 
Addison's disease, in those with T1D is about 2%. 
There is little evidence as yet that T1D patients 
should be routinely screened for this condition.1,44  
Multiple autoimmune endocrinopathies 
Multiple autoimmune endocrinopathies tend to 
segregate in definable groups; are termed 
autoimmune polyglandular syndromes (APS). Two 
broad groups were originally defined. T1D can 
occur in all of these, but is most frequent in APS 2 
(Table 3). APS 2 (Schmidt's Syndrome) is the 
commonest of the syndromes and is characterized 
by the presence of Addison's disease with T1D 
and/or autoimmune thyroiditis. APS 1 is 
characterized by the presence of at least two of 
Addison's disease, hypoparathyroidism and 
recurrent mucocutaneous candidiasis.1,49  
 
The future 
The greater understanding of the immunology of 
T1D led to several large studies conducted for 
diabetes prevention, some with promising results. 
Two strategies are open to physicians who have 
patients with T1D: the first is to prevent initiation 
of autoimmunity; the second is to reverse the 
effects of ongoing autoimmunity coupled with ß-
cell regeneration. Although highly ambitious, the 
prevention of T1D could be possible by identifying 
and eliminating environmental risk factors. The 
next line of defense would be to re-educate the 
immune system through exposure to ß -cell antigens 
with the use of oral or nasal tolerance strategies. 
The observation that insulin may be the primary 
autoantigen provides support for therapies using 
insulin to induce tolerance.1,6,20,25,29,50 In the 
meantime, immunological studies proved the 
association with other autoimmune diseases, that 
alter the morbidity of type1 diabetes. Clinically 
implemented, this understanding can help improve 
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Table 3. Autoimmune diseases associated with type 1diabetes44 
 









TPO 17–27% 28% 13% <1% overt 
 TG 8–16%  11% 5% subclinical 
Coeliac disease (CD) EMA 10% 4–9% <1% 0.9–1% 
 TTG 12%  1.5%  
Addison’s Disease 
(AD) 
21-OH 1.5% <0.5% Rare 0.005% 
Listed are autoimmune diseases associated with T1D, the prevalence of the autoantibodies, and disease in the general 
population and population with T1D.                  




Table 4. Selected genes associated with type 1 diabetes and related autoimmune diseases44 
 
Gene Associated diseases 
HLA  
DR3-DQ2, DR4-DQ8 T1D 





MIC-A T1D , CD, AD 
PTPN22 T1D , AIT , AD 
CTLA-4 T1D , AIT 




Table 5. Characteristics of the autoimmune polyglandular syndromes49 
 
 Type I Type II 
Incidence <1:100,000/yr 1–2:100,000/yr 
Male: female ratio 3:4 1:3 
Age at onset Childhood Adulthood 
Inheritance Monogenic autosomal-recessive Polygenic dominant 
HLA associations HLA-DRB1*03 (Addison’s disease) HLA DR3-DQB1*0201 
(multiple diseases) 
 HLA-DRB1*04-DQB1*0302 (alopecia) DR4-DQB1*0302 (T1D) 
 HLA-DRB1*15-DQB1*0602 (T1D) HLA-B8 (Graves’ disease) 
  HLA-B8/DRw3 
Candidiasis Mucocutaneous (70–80%) None 
Endocrinopathies Hypoparathyroidism (80–85%) Thyroid disease (70–75%) 
 Addison’s disease (60–70%) Type 1 diabetes (50–60%) 
 Type 1 diabetes (<20%) Addison’s disease (40–50%) 
 Hypogonadism (12%) Hypoparathyroidism (0–5%) 
 Thyroid disease (10%)  
 Hypopituitarism (0–2%)  
Nonendocrine autoimmune 
disorders 
Vitiligo, alopecia areata, autoimmune 
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